Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 juil. 2020 07h30 HE | Source: Ocugen

Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Disease

MALVERN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure...
21 juil. 2020 17h15 HE | Source: Ocugen

Ocugen to Present at World Orphan Drug Congress USA 2020 Conference

MALVERN, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to treat...
03 juin 2020 08h30 HE | Source: Ocugen

Ocugen Appoints Dr. Mohamed Genead as Chair of Retina Scientific Advisory Board

MALVERN, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
01 juin 2020 09h20 HE | Source: Ocugen

Ocugen to Discontinue Phase 3 oGVHD Trial

MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the...
08 mai 2020 07h30 HE | Source: Ocugen

Ocugen Provides Business Update and First Quarter 2020 Financial Results

MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the...
22 avr. 2020 09h38 HE | Source: Ocugen

Ocugen Announces Completion of Warrant Exchange

MALVERN, Pa., April 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
07 avr. 2020 08h01 HE | Source: Ocugen

Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors

MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
27 mars 2020 07h30 HE | Source: Ocugen

Ocugen Provides Business Update and Full Year 2019 Financial Results

Over 95% planned enrollment completed in Phase 3 oGVHD study; topline results anticipated by end of 2020 Conference Call and Webcast Today at 8:30 a.m. ET MALVERN, Pa., March 27, 2020 (GLOBE...
20 mars 2020 07h30 HE | Source: Ocugen

Ocugen to Host Conference Call on Friday, March 27 at 8:30 a.m. ET to Discuss 2019 Financial Results and Provide Business Update

MALVERN, Pa., March 20, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...
03 mars 2020 07h30 HE | Source: Ocugen

Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

MALVERN, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare...

Page précédente